Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
WALTHAM, Mass.
Amgen Announces 2019 Second Quarter Dividend
THOUSAND OAKS, Calif.
Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors
PLAINSBORO, N.
Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
CAMBRIDGE, Mass.
Protein inhibitor may help cure liver cancer: report
BEIJING, March 4 (Xinhua) -- Chinese scientists have identified a protein that causes the proliferation of liver cancer cells, a finding which could assist in the development of a new cancer d...
Ten years after the ‘Berlin patient,’ doctors announce a second person has been effectively ‘cured’ of HIV
For the second time, doctors appear to have put HIV into “sustained remission” with a stem cell transplant — effectively curing the recipient.
‘Wired into the walls’: Voice-recognition system promises to automate data entry during office visits
Hands down, the one task doctors complain about most is filling out the electronic health record during and after patient visits.
FDA approves esketamine, the first major depression treatment to reach U.S. market in decades
The Food and Drug Administration on Tuesday approved esketamine, the first major depression treatment to hit the U.
Biogen strikes $877M Nightstar gene therapy buyout
Biogen is set to pay $877 million (€772 million) to buy Nightstar Therapeutics for its pipeline of gene therapies.
BREAKING: FDA chief Scott Gottlieb steps down, leaving pet projects behind
In the past, AstraZeneca's investors have hit out at the company for executive compensation they deemed over-the-top.
AstraZeneca pays CEO Soriot nearly $15M after 2018's return to growth. Will investors push back?
In the past, AstraZeneca's investors have hit out at the company for executive compensation they deemed over-the-top.
Gilead to help HIV patients ‘Age Positively’ with $17.6M in grants to 30 groups
The face of HIV is aging.
384
385
386
387
388
389
390
391
392
